Amgen: Repatha Cuts Heart Attack Risk 20% Versus Ezetimibe
Image
THOUSAND OAKS – November 06, 2026 -- Amgen reported that Repatha (evolocumab) lowered the risk of fatal or nonfatal heart attack by 20% compared with ezetimibe in adults with atherosclerotic cardiovascular disease (ASCVD) and prior statin use. The real-world study followed 544,103 patients for up to four years and was published in The American Journal of Preventive Cardiology.
Four-year heart attack risk falls to 5.88% with Repatha versus 7.76% with ezetimibe
Among 225,048 patients with a baseline LDL-C measurement, the four-year cumulative risk of heart attack was 5.88% on Repatha and 7.76% on ezetimibe. Among patients without a baseline LDL-C measurement, the corresponding risks were 5.65% and 7.06%.
The primary outcome was fatal or nonfatal myocardial infarction. The hazard ratio was 0.80 (95% CI, 0.70-0.91).